oPatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
The anti-manic properties of lithium were first discovered by Australian psychiatrist John Cade in 1949. It is a mood stabiliser and has numerous effects on biological systems. It can substitute for sodium, potassium, calcium and magnesium in biological systems, and enters the cells and interferes with transmitter release and second messenger systems. Hence, it can block release of certain transmitters and hormones.
NB: unsuitable for children.
- Management of acute manic or hypomanic episodes.
- Prophylaxis of bipolar (manic-depressive) illness (co-administration of antidepressants may be needed in a depressive phase). Lithium is highly effective at reducing both relapses (particularly manic episodes) and suicide rate.
- Prophylaxis of recurrent depression and schizoaffective disorder.
- Augmentation of the antidepressant effect when it is co-prescribed with antidepressants in acute depressive illness.
- Prophylaxis of cluster headache (unlicensed indication).
- Control of aggressive behaviour or intentional self-harm and possibly suicidal behaviour. Lithium has been used successfully to reduce aggression in patients with learning disabilities who are unmanageable by environmental factors, and in patients with aggressive self-mutilating behaviour.
Before starting lithium
- Discuss with a psychiatrist - lithium should only be started under specialist supervision, weighing up the risks and benefits.
- If the patient is dangerously manic, refer for urgent admission.
- Lithium has a slow onset of action (7-14 days) so an antipsychotic may be needed initially - eg, haloperidol).
- Perform the following baseline tests:
- Measure weight, blood pressure and pulse.
- Ensure renal function is normal, as lithium is primarily excreted by the kidney. Measure serum creatinine, eGFR and possibly urine albumin:creatinine ratio (see reference for a good algorithm to follow).
- Check FBC, U&E, creatinine, TFT, calcium. NB: plasma lithium levels are increased by sodium depletion (competitive reabsorption at the renal level).
- Check there is no goitre, take blood for thyroid autoantibodies where there is a family history of thyroid disorders.
- It may be worth measuring baseline parathyroid hormone and magnesium.
- Perform baseline ECG.
Important drug interactions
- Angiotensin-converting enzyme (ACE) inhibitors
- Diuretics (particularly thiazides)
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Selective serotonin reuptake inhibitors (SSRIs) - sometimes co-prescribed
- Cardiac disease
- Significant renal impairment
- Addison's disease and patients with low body sodium levels
- Untreated hypothyroidism
Pregnancy and breast-feeding
- Pregnancy: avoid in first the trimester (teratogenic). Only use in the second and third trimester if considered essential, ie a severe risk to the patient, and monitor levels closely, as dose requirements may alter.
- Breast-feeding: avoid, as present in milk, and there is risk of toxicity in an infant. Bottle-feeding is advisable.
- Always prescribe non-generically by brand name - preparations may vary widely in bioavailability
- Inform patients:
- Of potential toxicity and symptoms of this (see 'Side-effects and toxicity', below).
- That they should ensure they have a regular fluid intake.
- Of the need for compliance in taking medication - reinforce this and that they should not stop or omit doses.
- Of the dangers of crash diets.
- To avoid NSAIDs.
- Not to exceed more than 1-2 units of alcohol per day.
- That it takes 3-6 months to be established on lithium.
- That lithium cards are available from pharmacists.
- The initial dose will depend on weight - use a lower dose in elderly patients.
- Check lithium levels (12 hours following dose):
- Five days following starting therapy or changing a dose.
- Then check levels weekly until levels have been stable for four weeks.
- Once levels have stabilised, check lithium levels every three months.
- Consider more frequent monitoring (eg, every two months) in the elderly, in those on interacting medication or in those with renal, thyroid or cardiac disease.
- Target concentrations:
- Acute episode (mania, hypomania, depression) 0.6-1.0 mmol/L (elderly 0.4-0.8 mmol/L).
- Prophylaxis of bipolar affective disorder 0.4-0.8 mmol/L.
- Toxic range usually >1.5 mmol/L; however, may begin at >1.0 mmol/L (levels >2 mmol/L need urgent treatment).
Monitoring lithium treatment
- Check lithium levels (12 hours post dose) at least every three months and during any intercurrent illness (can increase and cause toxicity).
- Therapeutic lithium levels: 0.4 to 1.0 mmol/L (may vary from laboratory to laboratory).
- At each consultation, ask about any signs of toxicity or signs of hypothyroidism.
- Check thyroid function, U&E, calcium and creatinine (and possibly urine dipstick for protein) every 6-12 months.
Side-effects and toxicity
- Lithium levels >1.5 mmol/L (>2.0 mmol/L may be associated with serious toxicity).
- Lithium toxicity should also be suspected at 'therapeutic' levels in compromised patients with relevant symptoms.
Common side-effects can usually be reduced or eliminated by lowering the lithium dose or changing the dosage schedule:
- Abdominal pain
- Metallic taste in the mouth (usually wears off)
- Fine tremor
- Thirst, polyuria, impaired urinary concentration - avoid fluid restriction
- Weight gain and oedema
- Cognitive impairment - presents as memory deficits, mild drowsiness
- Hyperparathyroidism and hypercalcaemia
- Nephrogenic diabetes insipidus
Toxicity may be due to intentional overdose, but it usually occurs during chronic treatment because of reduced drug excretion (dehydration, worsening renal function, concurrent infections, and drug interactions).
Stop lithium, check level, and refer for urgent assessment (encourage fluids, stop diuretics, monitor electrolytes and monitor renal function).
- Anorexia, diarrhoea and vomiting
- Drowsiness, apathy, restlessness
- Dizziness, ataxia, inco-ordination, muscle twitching, coarse tremor
Severe toxicity - admit as an emergency (whole bowel irrigation may be considered if large quantities have been ingested).
- Hyperreflexia, convulsions
- Collapse, coma
- Renal failure, dehydration, circulatory collapse (may need haemodialysis)
Abrupt withdrawal (both because of poor compliance or rapid change in dose) can precipitate relapse. Withdraw lithium slowly over several weeks, watching for relapse.
Further reading & references
- Lithium; Internet Mental Health
- Making sense of lithium and other mood stabilisers; MIND
- Safer Lithium Therapy, National Patient Safety Agency (2009)
- Evidence-based guidelines for treating bipolar disorder: revised second edition, British Association for Psychopharmacology (March 2009)
- The Management of bipolar disorder in adults, children and adolescents, in primary and secondary care; NICE (2006)
- Cade JF; Lithium salts in the treatment of psychotic excitement. 1949.; Bull World Health Organ. 2000;78(4):518-20.
- Summary of Product Characteristics (SPC) - Priadel® (lithium); Sanofi, electronic Medicines Compendium. Dated August 2006.
- Lithium Shared Care Protocol and Information for GPs; NHS Fife
- Cipriani A, Pretty H, Hawton K, et al; Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials.; Am J Psychiatry. 2005 Oct;162(10):1805-19.
- Geddes JR, Burgess S, Hawton K, et al; Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.; Am J Psychiatry. 2004 Feb;161(2):217-22.
- Depression in adults; NICE Clinical Guideline (October 2009)
- Headaches: diagnosis and management of headaches in young people and adults, NICE Clinical Guideline (September 2012)
- Capobianco DJ, Dodick DW; Diagnosis and treatment of cluster headache; Semin Neurol. 2006 Apr;26(2):242-59.
- Terao T; Aggression, suicide, and lithium treatment. Am J Psychiatry. 2008 Oct;165(10):1356-7; author reply 1357.
- Leucht S, Kissling W, McGrath J; Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials.; J Clin Psychiatry. 2004 Feb;65(2):177-86.
- Leucht S, McGrath J, Kissling W; Lithium for schizophrenia.; Cochrane Database Syst Rev. 2003;(3):CD003834.
- Kripalani M, Shawcross J, Reilly J, et al; Lithium and chronic kidney disease. BMJ. 2009 Jul 3;339:b2452. doi: 10.1136/bmj.b2452.
- McKnight RF, Adida M, Budge K, et al; Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012 Feb 25;379(9817):721-8. doi: 10.1016/S0140-6736(11)61516-X. Epub 2012 Jan 20.
- National Poisons Information Service
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
|Original Author: Dr Huw Thomas||Current Version: Dr Gurvinder Rull||Peer Reviewer: Dr John Cox|
|Last Checked: 02/05/2013||Document ID: 350 Version: 5||© EMIS|